Promote improvements coming to the PMC website in October 2024. Learn More or Take a survey.

Frontiers in Public Health

PMC 10879317

Front Public Health. 2024 Feb 14. 12:1329. doi: 10.3389/fpubh.1329 | PMCID: PMC10879317 | PMID: 37923496

Received: 11 Aug 2023 | Accepted: 25 Oct 2023 | Published online: 14 Feb 2024

Evaluation of cell phone support to one patient to promote healthcare in 33 adults

Sarvesh S. Kalsekar,[1] Ravi S. Kamble,[2] Vishwas Kalsekar,[3] Vaishali Kalsekar,[4] Vivek Hiremath,[5] Ashwini Kamble,[6] Ashwini Kalsekar,[7] Ashwini Kamble,[8] Ashwini Kalsekar,[9] Ashwini Kamble,[10] Ashwini Kalsekar,[11] Ashwini Kamble,[12] Ashwini Kalsekar,[13] Ashwini Kamble,[14] Ashwini Kalsekar,[15] Ashwini Kamble,[16] Ashwini Kalsekar,[17] Ashwini Kamble,[18] Ashwini Kalsekar,[19] Ashwini Kamble,[20] Ashwini Kalsekar,[21] Ashwini Kamble,[22] Ashwini Kalsekar,[23] Ashwini Kamble,[24] Ashwini Kalsekar,[25] Ashwini

6. Kulkarni AS, et al. Geroscience-guided repurposing of FDA-approved drugs to target aging: a proposed process and prioritization. *Aging Cell.* 2022;21:e13596. doi: 10.1111/acel.13596. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

7. Kaeberlein M, Rabinovitch PS, Martin GM. Healthy aging: the ultimate preventative medicine. *Science.* 2015;350:1191–1193. doi: 10.1126/science.aad3267. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Justice JN, et al. Development of clinical trials to extend healthy lifespan. *Cardiovasc Endocrinol Metab.* 2018;7:80–83. doi: 10.1097/XCE.0000000000000159. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

9. Wissler Gerdes EO, Misra A, Netto JME, Tchkonia T, Kirkland JL. Strategies for late phase preclinical and early clinical trials of senolytics. *Mech Ageing Dev.* 2021;200:111591. doi: 10.1016/j.mad.2021.111591. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

10. Romashkan S, Chang H, Hadley EC. National Institute on Aging Workshop: repurposing drugs or dietary supplements for their senolytic or senomorphic effects: considerations for clinical trials. *J Gerontol A Biol Sci Med Sci.* 2021;76:1144–1152. doi: 10.1093/gerona/glab028. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

11. Vaiserman A, Koliada A, Lushchak O, Castillo MJ. Repurposing drugs to fight aging: the difficult path from bench to bedside. *Med Res Rev.* 2021;41:1676–1700. doi: 10.1002/med.21773. [PubMed] [CrossRef] [Google Scholar]

12. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. *Nature.* 2013;493:338–345. doi: 10.1038/nature11861. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Kennedy BK, Lamming DW. The mechanistic target of rapamycin: the grand conducTOR of metabolism and aging. *Cell Metab.* 2016;23:990–1003. doi: 10.1016/j.cmet.2016.05.009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Powers RW, 3rd, Kaeberlein M, Caldwell SD, Kennedy BK, Fields S. Extension of chronological life span in yeast by decreased TOR pathway signaling. *Genes Dev.* 2006;20:174–184. doi: 10.1101/gad.1381406. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Medvedik O, Lamming DW, Kim KD, Sinclair DA. MSN2 and MSN4 link calorie restriction and TOR to sirtuin-mediated lifespan extension in Saccharomyces cerevisiae. *PLoS Biol.* 2007;5:e261. doi: 10.1371/journal.pbio.0050261. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

16. Robida-Stubbs S, et al. TOR signaling and rapamycin influence longevity by regulating SKN-1/Nrf and DAF-16/FoxO. *Cell Metab.* 2012;15:713–724. doi: 10.1016/j.cmet.2012.04.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

17. Bjedov I, et al. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. *Cell Metab.* 2010;11:35–46. doi: 10.1016/j.cmet.2009.11.010. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Lu YX, et al. A TORC1-histone axis regulates chromatin organisation and non-canonical induction of autophagy to ameliorate ageing. eLife. 2021;10:e62233. [PMC free article] [PubMed]

19. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature.* 2009;460:392–395. doi: 10.1038/nature08221. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

20. Anisimov VN, et al. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. *Cell Cycle.* 2011;10:4230–4236. doi: 10.4161/cc.10.24.18486. [PubMed] [CrossRef] [Google Scholar]

21. Komarova EA, et al. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. *Aging (Albany NY)* 2012;4:709–714. doi: 10.18632/aging.100498. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Wilkinson JE, et al. Rapamycin slows aging in mice. *Aging Cell.* 2012;11:675–682. doi: 10.1111/j.1474-9726.2012.00832.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

23. Livi CB, et al. Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors. *Aging (Albany NY)* 2013;5:100–110. doi: 10.18632/aging.100533. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

24. Neff F, et al. Rapamycin extends murine lifespan but has limited effects on aging. *J Clin Investig.* 2013;123:3272–3291. doi: 10.1172/JCI67674. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Fok WC, et al. Mice fed rapamycin have an increase in lifespan associated with major changes in the liver transcriptome. *PLoS ONE.* 2014;9:e83988. doi: 10.1371/journal.pone.0083988. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. Miller RA, et al. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. *Aging Cell.* 2014;13:468–477. doi: 10.1111/acel.12194. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Popovich IG, et al. Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin. *Cancer Biol Ther.* 2014;15:586–592. doi: 10.4161/cbt.28164. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

28. Bitto A, et al. Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice. eLife. 2016;5:e16351. [PMC free article] [PubMed]

29. Miller RA, et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. *J Gerontol A Biol Sci Med Sci.* 2011;66:191–201. doi: 10.1093/gerona/glq178. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

30. Zhang Y, et al. Rapamycin extends life and health in C57BL/6 mice. *J Gerontol A Biol Sci Med Sci.* 2014;69:119–130. doi: 10.1093/gerona/glt056. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

31. Halloran J, et al. Chronic inhibition of mammalian target of rapamycin by rapamycin modulates cognitive and non-cognitive components of behavior throughout lifespan in mice. *Neuroscience.* 2012;223:102–113. doi: 10.1016/j.neuroscience.2012.06.054. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

32. Majumder S, et al. Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1beta and enhancing NMDA signaling. *Aging Cell.* 2012;11:326–335. doi: 10.1111/j.1474-9726.2011.00791.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. Shavlakadze T, et al. Short-term low-dose mTORC1 inhibition in aged rats counter-regulates age-related gene changes and blocks age-related kidney pathology. *J Gerontol A Biol Sci Med Sci.* 2018;73:845–852. doi: 10.1093/gerona/glx249. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

34. Zaseck LW, Miller RA, Brooks SV. Rapamycin attenuates age-associated changes in tibialis anterior tendon viscoelastic properties. *J Gerontol A Biol Sci Med Sci.* 2016;71:858–865. doi: 10.1093/gerona/glv307. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

35. Yilmaz OH, et al. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. *Nature.* 2012;486:490–495. doi: 10.1038/nature11163. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

36. Garcia DN, et al. Effect of caloric restriction and rapamycin on ovarian aging in mice. *Geroscience.* 2019;41:395–408. doi: 10.1007/s11357-019-00087-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

37. Altschuler RA, et al. Rapamycin added to diet in late mid-life delays age-related hearing loss in UMHET4 mice. *Front Cell Neurosci.* 2021;15:658972. doi: 10.3389/fncel.2021.658972. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

38. Chiao YA, et al. Rapamycin transiently induces mitochondrial remodeling to reprogram energy metabolism in old hearts. *Aging (Albany NY)* 2016;8:314–327. doi: 10.18632/aging.100881. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Dai DF, et al. Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. *Aging Cell.* 2014;13:529–539. doi: 10.1111/acel.12203. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

40. Flynn JM, et al. Late-life rapamycin treatment reverses age-related heart dysfunction. *Aging Cell.* 2013;12:851–862. doi: 10.1111/acel.12109. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

41. Chen C, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal. 2009;2:ra75. [PMC free article] [PubMed]

42. An JY, et al. Rapamycin rejuvenates oral health in aging mice. eLife. 2020;9:e54318. [PMC free article] [PubMed]

43. An JY, et al. Rapamycin treatment attenuates age-associated periodontitis in mice. *Geroscience.* 2017;39:457–463. doi: 10.1007/s11357-017-9994-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

44. Urfer SR, et al. A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs. *Geroscience.* 2017;39:117–127. doi: 10.1007/s11357-017-9972-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

45. Mannick JB, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6:268ra179. [PubMed]

46. Mannick JB, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med. 2018;10:eaaq1564. [PubMed]

47. Kaeberlein M. mTOR inhibition: from aging to autism and beyond. Scientifica (Cairo). 2013;2013:849186. [PMC free article] [PubMed]

48. Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. *Drug Saf.* 2005;28:153–181. doi: 10.2165/00002018-200528020-00006. [PubMed] [CrossRef] [Google Scholar]

49. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. *Transpl Proc.* 2003;35:7S–14S. doi: 10.1016/S0041-1345(03)00211-2. [PubMed] [CrossRef] [Google Scholar]

50. Cox LS, et al. Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults. Lancet Healthy Longev. 2020;1:e55–e57. [PMC free article] [PubMed]

51. Mannick JB, et al. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. *Lancet Healthy Longev.* 2021;2:e250–e262. doi: 10.1016/S2666-7568(21)00062-3. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

52. Kraig E, et al. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. *Exp Gerontol.* 2018;105:53–69. doi: 10.1016/j.exger.2017.12.026. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

53. de Oliveira MA, et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis. *Oral Oncol.* 2011;47:998–1003. doi: 10.1016/j.oraloncology.2011.08.009. [PubMed] [CrossRef] [Google Scholar]

54. Saigal B, Guerra L. Prevention of stomatitis: using dexamethasone-based mouthwash to inhibit everolimus-related stomatitis. *Clin J Oncol Nurs.* 2018;22:211–217. doi: 10.1188/18.CJON.211-217. [PubMed] [CrossRef] [Google Scholar]

55. Bischof E, Siow RC, Zhavoronkov A, Kaeberlein M. The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19. *Lancet Healthy Longev.* 2021;2:e105–e111. doi: 10.1016/S2666-7568(20)30068-4. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

56. Blagosklonny MV. From causes of aging to death from COVID-19. *Aging (Albany NY)* 2020;12:10004–10021. doi: 10.18632/aging.103493. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

57. Mehandru S, Merad M. Pathological sequelae of long-haul COVID. *Nat Immunol.* 2022;23:194–202. doi: 10.1038/s41590-021-01104-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

58. Bitto A, Tatom N, Krivak T, Grotz P, Kaeberlein M. Evidence that C/EBP-beta LAP increases fat metabolism and protects against diet-induced obesity in response to mTOR inhibition. *Front Aging.* 2021;2:738512. doi: 10.3389/fragi.2021.738512. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

59. Um SH, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. *Nature.* 2004;431:200–205. doi: 10.1038/nature02866. [PubMed] [CrossRef] [Google Scholar]

60. Chang GR, et al. Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. *J Pharmacol Sci.* 2009;109:496–503. doi: 10.1254/jphs.08215FP. [PubMed] [CrossRef] [Google Scholar]

61. Makki K, et al. Beneficial metabolic effects of rapamycin are associated with enhanced regulatory cells in diet-induced obese mice. *PLoS ONE.* 2014;9:e92684. doi: 10.1371/journal.pone.0092684. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

62. Sataranatarajan K, et al. Rapamycin increases mortality in db/db mice, a mouse model of type 2 diabetes. *J Gerontol A Biol Sci Med Sci.* 2016;71:850–857. doi: 10.1093/gerona/glv170. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

63. Jacobson TA, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. *J Clin Lipidol.* 2019;13:415–424. doi: 10.1016/j.jacl.2019.04.011. [PubMed] [CrossRef] [Google Scholar]

64. de Vries ST, Denig P, Ekhart C, Mol PGM, van Puijenbroek EP. Sex differences in adverse drug reactions of metformin: a longitudinal survey study. *Drug Saf.* 2020;43:489–495. doi: 10.1007/s40264-020-00913-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

Articles from GeroScience are provided here courtesy of **Springer**

FOLLOW NCBI

Connect with NLM

National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894

Web Policies
FOIA
HHS Vulnerability Disclosure

Help
Accessibility
Careers

NLM | NIH | HHS | USA.gov

Feedback